Share on StockTwits

Smith & Nephew plc (LON:SN)‘s stock had its “outperform” rating restated by investment analysts at Sanford C. Bernstein in a note issued to investors on Wednesday. They currently have a GBX 1,160 ($19.69) price target on the stock. Sanford C. Bernstein’s price objective indicates a potential upside of 8.31% from the stock’s previous close.

SN has been the subject of a number of other recent research reports. Analysts at BNP Paribas reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Monday. They now have a GBX 1,000 ($16.98) price target on the stock. Separately, analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Wednesday, June 11th. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Monday, June 9th. They now have a GBX 1,125 ($19.10) price target on the stock. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of GBX 935.60 ($15.88).

Smith & Nephew plc (LON:SN) opened at 1067.00 on Wednesday. Smith & Nephew plc has a one year low of GBX 720.00 and a one year high of GBX 1136.00. The stock has a 50-day moving average of GBX 980.7 and a 200-day moving average of GBX 915.1. The company’s market cap is £9.528 billion.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.